Navigating the complex terrain of hepatitis B virus reactivation in the era of Bruton tyrosine kinase inhibitors

World J Gastroenterol. 2024 Jun 7;30(21):2748-2750. doi: 10.3748/wjg.v30.i21.2748.

Abstract

In this editorial, we offer a summary of the risk associated with hepatitis B reactivation (HBVr) in the setting of both solid and hematologic malignancies treated with Bruton tyrosine kinase (BTK) inhibitors, with insights derived from current studies. Furthermore, we emphasize the critical need for a framework regarding robust risk evaluation in patients undergoing such treatments. This framework is essential for identifying those at increased risk of HBVr, enabling healthcare providers to implement proactive measures to prevent reactivation and ensure the safe administration of BTK inhibitor therapy.

Keywords: Bruton tyrosine kinase inhibitors; Hematologic malignancies; Hepatitis B virus reactivation; Prophylaxis guidelines; Solid tumors.

Publication types

  • Editorial

MeSH terms

  • Agammaglobulinaemia Tyrosine Kinase* / antagonists & inhibitors
  • Antiviral Agents / therapeutic use
  • Hematologic Neoplasms / drug therapy
  • Hematologic Neoplasms / virology
  • Hepatitis B / drug therapy
  • Hepatitis B / virology
  • Hepatitis B virus* / drug effects
  • Hepatitis B, Chronic / drug therapy
  • Hepatitis B, Chronic / virology
  • Humans
  • Protein Kinase Inhibitors* / adverse effects
  • Protein Kinase Inhibitors* / therapeutic use
  • Risk Assessment
  • Tyrosine Kinase Inhibitors
  • Virus Activation* / drug effects

Substances

  • Agammaglobulinaemia Tyrosine Kinase
  • Protein Kinase Inhibitors
  • BTK protein, human
  • Antiviral Agents
  • Tyrosine Kinase Inhibitors